{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:07:55Z","timestamp":1779275275702,"version":"3.51.4"},"reference-count":67,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014173","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:30:39Z","timestamp":1779273039000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activity"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2611-5562","authenticated-orcid":false,"given":"Yuanteng J","family":"Li","sequence":"additional","affiliation":[{"name":"General Internal Medicine - Rheumatology; The University of Texas MD Anderson Cancer Center; Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-8393","authenticated-orcid":false,"given":"Maria Angeles","family":"Lopez-Olivo","sequence":"additional","affiliation":[{"name":"Department of Health Services Research; The University of Texas, MD Anderson Cancer Center; Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-3151","authenticated-orcid":false,"given":"Yimin","family":"Geng","sequence":"additional","affiliation":[{"name":"Research Medical Library; The University of Texas MD Anderson Cancer Center; Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9018-3802","authenticated-orcid":false,"given":"Jean H","family":"Tayar","sequence":"additional","affiliation":[{"name":"General Internal Medicine - Rheumatology; The University of Texas, MD Anderson Cancer Center; Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-5797","authenticated-orcid":false,"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"General Internal Medicine - Rheumatology; The University of Texas, MD Anderson Cancer Center; Houston Texas USA"},{"name":"Health Services Research; The University of Texas MD Anderson Cancer Center; Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD014173-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis\u2014common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014173-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","article-title":"The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review","volume":"41","author":"Almutairi","year":"2021","journal-title":"Rheumatology International"},{"issue":"6","key":"10.1002\/14651858.CD014173-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/annrheumdis-2019-216243","article-title":"Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era","volume":"79","author":"Hsieh","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD014173-BIB0004|cit4","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nature Reviews in Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD014173-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016 update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD014173-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD014173-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","article-title":"Biosimilars: key regulatory considerations and similarity assessment tools","volume":"114","author":"Kirchhoff","year":"2017","journal-title":"Biotechnology and Bioengineering"},{"issue":"8","key":"10.1002\/14651858.CD014173-BIB0008|cit8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010227.pub2","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis","author":"Hazlewood","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"52","key":"10.1002\/14651858.CD014173-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/imj.15816","article-title":"Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis","volume":"10","author":"Whittle","year":"2024","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD014173-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"746396","DOI":"10.3389\/fphar.2021.746396","article-title":"Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD014173-BIB0011|cit11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050876","article-title":"Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?","volume":"13","author":"Zhang","year":"2022","journal-title":"Frontiers Immunology"},{"issue":"11","key":"10.1002\/14651858.CD014173-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"e2446336","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1002\/14651858.CD014173-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/rheumatology\/keaf096","article-title":"Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis","volume":"64","author":"Sendaydiego","year":"2025","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD014173-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.55563\/clinexprheumatol\/beucf1","article-title":"One year in review 2021: novelties in the treatment of rheumatoid arthritis","volume":"39","author":"Silvagni","year":"2021","journal-title":"Clincal Experimental Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/rheumatology\/key132","article-title":"Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature","volume":"57","author":"Ruscitti","year":"2018","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD014173-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010455.pub3","article-title":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","author":"Verhoef","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD014173-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care & Research"},{"issue":"1","key":"10.1002\/14651858.CD014173-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD014173-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","article-title":"bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search","volume":"4","author":"Verhoef","year":"2017","journal-title":"Rheumatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD014173-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","article-title":"Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study","volume":"74","author":"Tanaka","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD014173-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and metaanalyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0022|cit22","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Methodological Expectations of Cochrane Intervention Reviews Cochrane: London,"},{"key":"10.1002\/14651858.CD014173-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014173-BIB0024|cit24","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Technical Supplement to Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"issue":"9","key":"10.1002\/14651858.CD014173-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD014173-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0027|cit27","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clinical Experimental Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0028|cit28","first-page":"S93","article-title":"The disease activity score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clinical Experimental Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD014173-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard-2023-224742","article-title":"Definition of rheumatoid arthritis flare based on SDAI and CDAI","volume":"83","author":"Konzett","year":"2024","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD014173-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD014173-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1745-6215-14-324","article-title":"Outcome measures in rheumatoid arthritis randomised trials over the last 50 years","volume":"14","author":"Kirkham","year":"2013","journal-title":"Trials"},{"issue":"12","key":"10.1002\/14651858.CD014173-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015880","article-title":"Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity","author":"Ramsay","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014173-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI): concepts, measurement properties and applications","volume":"1","author":"Horsman","year":"2003","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"10.1002\/14651858.CD014173-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/art.1780230203","article-title":"Measuring health status in arthritis. The arthritis impact measurement scales","volume":"23","author":"Meenan","year":"1980","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD014173-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/rheumatology\/36.8.884","article-title":"Quality of life in rheumatoid arthritis","volume":"36","author":"Whalley","year":"1997","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD014173-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"10.1002\/14651858.CD014173-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Annals of the Rheumatic Disease"},{"key":"10.1002\/14651858.CD014173-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/03009747509165261","article-title":"A radiological method for grading the severity of rheumatoid arthritis","volume":"4","author":"Larsen","year":"1973","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0042|cit42","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"Heijde","year":"2000","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"33","author":"Prevoo","year":"1995","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"Heijde","year":"1990","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD014173-BIB0045|cit45","unstructured":"EndNote 20 Clarivate 2013"},{"key":"10.1002\/14651858.CD014173-BIB0046|cit46","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD014173-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014173-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/1471-2458-13-658","article-title":"The grounded theory, psychometric development and initial validation of the Health Literacy Questionnaire (HLQ)","volume":"13","author":"Osborne","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD014173-BIB0049|cit49","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD014173-BIB0050|cit50","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD014173-BIB0051|cit51","unstructured":"WebPlotDigitizer Rohatgi A Ankit Rohatgi 2021"},{"key":"10.1002\/14651858.CD014173-BIB0052|cit52","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014173-BIB0053|cit53","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.2.0"},{"key":"10.1002\/14651858.CD014173-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles\u2014continuous outcomes","volume":"66","author":"Guyatt","year":"2012","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014173-BIB0055|cit55","unstructured":"Higgins JPT Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD014173-BIB0056|cit56","unstructured":"Deeks JJ Higgins JP Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD014173-BIB0057|cit57","unstructured":"Page MJ Higgins JPT Sterne JAC Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD014173-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/acr.20349","article-title":"Reaching those most in need: a scoping review of interventions to improve health care quality for disadvantaged populations with osteoarthritis","volume":"63","author":"Borkhoff","year":"2011","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD014173-BIB0059|cit59","unstructured":"World Health Organization Health Promotion Glossary https:\/\/iris.who.int\/bitstream\/handle\/10665\/64546\/WHO_HPR_HEP_98.1.pdf?sequence=1"},{"key":"10.1002\/14651858.CD014173-BIB0060|cit60","volume-title":"Health Literacy: A Prescription to End Confusion","author":"Committee on Health Literacy","year":"2004"},{"key":"10.1002\/14651858.CD014173-BIB0061|cit61","unstructured":"Commonwealth of Australia A healthier future for all Australians\u2014final report of the National Health and Hospitals Reform Commission https:\/\/cotasa.org.au\/assets\/volumes\/downloads\/News\/NHHRC_Report.pdf"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014173-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10810730.2010.499996","article-title":"Health literacy and the Millennium Development Goals: United Nations Economic and Social Council (ECOSOC) regional meeting background paper (abstracted)","volume":"15","author":"United Nations Economic and Social Council (ECOSOC)","year":"2010","journal-title":"Journal of Health Communication"},{"key":"10.1002\/14651858.CD014173-BIB0063|cit63","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"issue":"1","key":"10.1002\/14651858.CD014173-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/imj.14191","article-title":"Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network","volume":"50","author":"Buchbinder","year":"2020","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD014173-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/1756-185X.14926","article-title":"Prioritization of clinical questions for the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis","volume":"26","author":"Glennon","year":"2023","journal-title":"International Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014173-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1745-6215-14-324","article-title":"Outcome measures in rheumatoid arthritis randomised trials over the last 50 years","volume":"14","author":"Kirkham","year":"2013","journal-title":"Trials"},{"key":"10.1002\/14651858.CD014173-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.2023-0530","article-title":"Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT working group","volume":"50","author":"Leung","year":"2023","journal-title":"Journal of Rheumatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:30:54Z","timestamp":1779273054000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014173"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":67,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014173","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}